Ikena Oncology Inc
IKNA1.430USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
69.01MMarket Cap
LossP/E TTM
More Details of Ikena Oncology Inc Company
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.
Ikena Oncology Inc Info
Ticker SymbolIKNA
Company nameIkena Oncology Inc
IPO dateMar 26, 2021
CEODr. Mark Manfredi, Ph.D.
Number of employees10
Security typeOrdinary Share
Fiscal year-endMar 26
Address645 Summer Street
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02210
Phone18572738343
Websitehttps://www.ikenaoncology.com
Ticker SymbolIKNA
IPO dateMar 26, 2021
CEODr. Mark Manfredi, Ph.D.
Company Executives of Ikena Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Erin Butler
Ms. Erin Butler
Senior Vice President - Finance, Administration
Senior Vice President - Finance, Administration
3.05K
+1101.18%
Dr. Yufang Lu, M.D., Ph.D.
Dr. Yufang Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Kristin Yarema, Ph.D.
Dr. Kristin Yarema, Ph.D.
Chief Executive Officer, Interim Principal Financial Officer, Director
Chief Executive Officer, Interim Principal Financial Officer, Director
--
--
Mr. Joseph P. Slattery
Mr. Joseph P. Slattery
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Erin Butler
Ms. Erin Butler
Senior Vice President - Finance, Administration
Senior Vice President - Finance, Administration
3.05K
+1101.18%
Dr. Yufang Lu, M.D., Ph.D.
Dr. Yufang Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Kristin Yarema, Ph.D.
Dr. Kristin Yarema, Ph.D.
Chief Executive Officer, Interim Principal Financial Officer, Director
Chief Executive Officer, Interim Principal Financial Officer, Director
--
--
Mr. Joseph P. Slattery
Mr. Joseph P. Slattery
Director
Director
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Engene Inc
9.12%
Deep Track Capital LP
8.25%
BVF Partners L.P.
7.53%
Blue Owl Capital Holdings LP
5.08%
Omega Fund Management, LLC
4.28%
Other
65.75%
Shareholders
Shareholders
Proportion
Engene Inc
9.12%
Deep Track Capital LP
8.25%
BVF Partners L.P.
7.53%
Blue Owl Capital Holdings LP
5.08%
Omega Fund Management, LLC
4.28%
Other
65.75%
Shareholder Types
Shareholders
Proportion
Hedge Fund
17.61%
Corporation
10.79%
Investment Advisor
9.94%
Venture Capital
9.01%
Investment Advisor/Hedge Fund
4.02%
Individual Investor
3.89%
Private Equity
3.55%
Research Firm
0.02%
Other
41.17%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
144
3.83M
34.29%
-144.69K
2025Q2
151
3.09M
56.79%
-426.62K
2025Q1
153
37.18M
88.76%
-11.63M
2024Q4
152
42.51M
88.10%
+3.24M
2024Q3
158
35.71M
75.76%
-7.30M
2024Q2
157
41.92M
101.46%
-2.84M
2024Q1
144
43.23M
104.60%
-1.89M
2023Q4
138
45.31M
109.56%
+9.57M
2023Q3
139
34.27M
91.14%
-685.32K
2023Q2
137
32.75M
91.43%
+3.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Engene Inc
971.17K
8.69%
+971.17K
--
Sep 08, 2025
Deep Track Capital LP
878.52K
7.86%
--
--
Sep 08, 2025
BVF Partners L.P.
802.10K
7.17%
+468.22K
+140.24%
Sep 08, 2025
Blue Owl Capital Holdings LP
340.93K
3.05%
--
--
Jun 30, 2025
Omega Fund Management, LLC
187.43K
1.68%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
378.94K
3.39%
+379.00
+0.10%
Sep 08, 2025
Atlas Venture
418.18K
3.74%
-3.00
-0.00%
Jul 28, 2025
Wang (Stephen Hui)
250.72K
2.24%
+250.72K
--
Sep 08, 2025
The Vanguard Group, Inc.
117.80K
1.05%
+2.52K
+2.19%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ikena Oncology Inc?
The top five shareholders of Ikena Oncology Inc are:
Engene Inc holds 971.17K shares, accounting for 8.69% of the total shares.
Deep Track Capital LP holds 878.52K shares, accounting for 7.86% of the total shares.
BVF Partners L.P. holds 802.10K shares, accounting for 7.17% of the total shares.
Blue Owl Capital Holdings LP holds 340.93K shares, accounting for 3.05% of the total shares.
Omega Fund Management, LLC holds 187.43K shares, accounting for 1.68% of the total shares.
Engene Inc holds 971.17K shares, accounting for 8.69% of the total shares.
Deep Track Capital LP holds 878.52K shares, accounting for 7.86% of the total shares.
BVF Partners L.P. holds 802.10K shares, accounting for 7.17% of the total shares.
Blue Owl Capital Holdings LP holds 340.93K shares, accounting for 3.05% of the total shares.
Omega Fund Management, LLC holds 187.43K shares, accounting for 1.68% of the total shares.
What are the top three shareholder types of Ikena Oncology Inc?
The top three shareholder types of Ikena Oncology Inc are:
Engene Inc
Deep Track Capital LP
BVF Partners L.P.
Engene Inc
Deep Track Capital LP
BVF Partners L.P.
How many institutions hold shares of Ikena Oncology Inc (IKNA)?
As of 2025Q3, 144 institutions hold shares of Ikena Oncology Inc, with a combined market value of approximately 3.83M, accounting for 34.29% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.50%.
What is the biggest source of revenue for Ikena Oncology Inc?
In FY2024, the -- business generated the highest revenue for Ikena Oncology Inc, amounting to -- and accounting for --% of total revenue.
